Company intelligence / Profile preview

Reticula

Ownership: Private
Development stage: Other

Overview

Reticula is developing an innovative single molecule DNA sequencing platform that aims to dramatically reduce costs and complexity compared to existing technologies. The approach eliminates fluidic systems and complex reagent cartridges, targeting $1 per run consumable costs and $500 instrument price points. The company has raised initial angel funding to advance its prototype development. No clinical results are relevant as this is not a therapeutics developer.

Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Reticula.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reticula.

Explore the full profile